Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000667)

(Analysis AN001020)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8
lysoPE 24:0; [M-H]-@5.25	ME182107	0.06	0.83	0.21	2.08	0.03	0.81	0.14	2.34
CL 74:9; [M-2H](2-)@5.75	ME181831	2.44	1.30	0.48	0.56	3.70	1.11	0.65	0.54
lysoPE 16:1; [M-H]-@1.20	ME182096	0.25	2.35	0.06	1.28	0.44	1.71	0.13	1.68
lysoPE 22:6; [M-H]-@1.28	ME182106	0.15	4.80	0.19	0.07	0.21	4.70	0.39	0.07
FFA(22:2)	ME181856	0.56	3.40	0.36	0.77	0.28	2.89	0.29	0.56
lysoPE 20:1; [M-H]-@2.57	ME182100	0.24	2.66	0.21	1.13	0.23	2.03	0.13	1.44
FFA(24:2)	ME181860	0.43	2.14	0.24	1.59	0.47	1.55	0.21	1.24
PA 36:2; [M-H]-@5.87	ME181870	0.13	0.27	0.18	2.35	0.14	0.46	0.23	2.47
FFA(22:3)	ME181857	0.21	5.62	0.21	0.19	0.09	1.05	0.24	0.16
CL 72:1; [M-2H](2-)@7.12	ME181818	0.06	0.56	0.10	2.82	0.09	0.61	0.16	1.92
CL 76:7; [M-2H](2-)@6.75	ME181836	2.14	1.89	0.32	0.81	2.19	0.64	0.48	0.69
CL 78:4; [M-2H](2-)@7.02	ME181839	1.38	1.05	1.10	0.81	1.47	0.49	1.33	0.53
FFA(20:0)	ME181851	0.22	3.60	0.56	0.42	0.17	3.45	0.69	0.30
FFA(22:0)	ME181854	0.22	2.11	0.51	1.28	0.26	2.02	0.56	1.08
FFA(20:2)	ME181853	0.16	5.68	0.12	0.14	0.09	2.33	0.15	0.10
IS PI 37:4 ;[M-H]-	ME181865	0.04	2.96	0.92	0.23	0.04	3.05	1.43	0.20
IS PC 34:0;[M-Ac-H]-	ME181862	0.18	1.91	1.52	0.30	0.21	2.35	1.71	0.22
lysoPE 20:3; [M-H]-@1.58	ME182101	0.13	5.46	0.04	0.09	0.12	3.57	0.13	0.15
PA 35:1; [M-H]-@6.12	ME181868	0.10	0.40	0.43	2.06	0.04	0.27	0.55	2.19
FFA(16:0)	ME181847	0.17	3.21	0.62	0.56	0.17	3.20	0.80	0.39
CL 74:7; [M-2H](2-)@6.03	ME181829	1.97	0.84	0.52	1.71	1.58	0.41	0.53	0.68
CL 80:7; [M-2H](2-)@7.02	ME181842	1.84	1.47	0.80	0.76	2.53	1.56	0.60	0.50
FFA(18:0)	ME181848	0.17	3.23	0.68	0.52	0.17	2.76	0.90	0.36
CL 72:8; [M-2H](2-)@8.97	ME181824	1.39	0.45	1.31	0.83	0.88	0.72	1.87	0.35
CL 78:13; [M-2H](2-)@5.75	ME181838	2.72	0.57	0.54	0.84	3.31	0.79	0.74	0.68
CL 82:5; [M-2H](2-)@7.64	ME181845	0.43	0.55	1.22	1.08	0.24	0.34	1.84	0.90
CL 76:12; [M-2H](2-)@8.88	ME181835	1.19	1.33	0.69	0.46	1.01	1.43	1.27	1.06
lysoPE 18:0; [M-H]-@2.46	ME182097	0.84	3.74	0.25	0.33	1.39	2.76	0.42	0.32
CL 82:15; [M-2H](2-)@5.93	ME181843	1.16	0.18	1.20	1.41	0.95	0.10	1.29	0.90
FFA(24:3)	ME181861	0.62	2.06	0.20	1.35	0.54	3.67	0.34	0.89
CL 76:1; [M-2H](2-)@5.86	ME181833	0.04	0.93	0.16	2.58	0.15	0.64	0.10	1.86
IS PG 34:0 ;[M-H]-	ME181864	0.05	2.80	1.11	0.20	0.07	3.55	1.41	0.11
CL 72:7; [M-2H](2-)@9.17	ME181822	1.70	0.36	1.35	0.36	1.35	0.13	2.27	0.28
CL 66:1; [M-2H](2-)@6.24	ME181812	0.16	0.10	0.47	2.67	0.27	0.14	0.31	1.99
lysoPE 18:1; [M-H]-@1.81	ME182098	0.20	0.92	0.05	2.01	0.17	0.67	0.07	2.45
CL 72:3; [M-2H](2-)@6.43	ME181819	0.19	1.19	0.09	1.96	0.29	0.41	0.09	2.28
CL 78:1; [M-2H](2-)@7.71	ME181837	0.11	0.39	0.39	2.49	0.13	0.15	0.52	1.85
CL 70:1; [M-2H](2-)@5.34	ME181815	0.05	1.21	0.31	1.83	0.08	1.02	0.28	2.03
lysoPE 22:5; [M-H]-@1.49	ME182105	0.12	4.92	0.11	0.25	0.12	3.96	0.18	0.25
CL 80:13; [M-2H](2-)@6.11	ME181841	1.21	0.40	1.05	1.49	1.32	0.74	1.01	0.80
lysoPE 18:2; [M-H]-@1.37	ME182099	0.08	5.85	0.01	0.14	0.07	2.91	0.02	0.12
PA 38:3; [M-H]-@5.97	ME181873	0.27	0.27	0.13	2.46	0.31	0.78	0.18	2.25
CL 86:13; [M-2H](2-)@7.00	ME181846	0.15	0.50	1.75	1.29	0.01	0.16	1.71	0.67
FFA(18:1)	ME181849	0.07	5.32	0.07	0.21	0.06	3.82	0.08	0.18
CL 74:5; [M-2H](2-)@5.93	ME181827	0.44	0.81	0.13	3.16	0.33	0.11	0.13	1.20
CL 70:5; [M-2H](2-)@6.06	ME181816	0.43	0.61	0.29	2.50	0.47	0.27	0.22	1.75
CL 74:3; [M-2H](2-)@6.22	ME181826	0.80	1.46	0.24	1.83	0.66	0.74	0.23	1.42
CL 66:3; [M-2H](2-)@5.71	ME181813	0.38	0.24	0.74	2.05	0.33	0.58	0.23	2.12
CL 68:1; [M-2H](2-)@6.56	ME181814	0.08	0.43	0.12	2.51	0.06	0.27	0.16	2.37
CL 70:7; [M-2H](2-)@5.44	ME181817	0.46	0.70	0.58	1.97	0.64	1.73	0.41	1.45
CL 72:6; [M-2H](2-)@9.35	ME181821	2.02	0.30	1.40	0.31	0.78	0.46	2.05	0.43
CL 74:11; [M-2H](2-)@5.55	ME181825	1.99	0.74	0.94	0.57	2.60	0.84	1.42	0.39
CL 74:5; [M-2H](2-)@6.56	ME181828	1.11	1.09	0.37	1.93	0.94	0.46	0.37	1.18
PA 38:1; [M-H]-@6.88	ME181871	0.01	0.22	0.08	3.01	0.02	0.04	0.02	2.31
PA 34:1; [M-H]-@5.74	ME181867	0.07	0.32	0.10	2.21	0.03	0.92	0.25	2.57
PA 38:2; [M-H]-@6.41	ME181872	0.13	0.47	0.13	2.54	0.10	0.61	0.17	2.20
CL 72:5; [M-2H](2-)@9.52	ME181820	0.55	0.59	1.69	0.43	0.43	0.28	2.61	0.26
CL 74:8; [M-2H](2-)@9.21	ME181830	1.12	0.58	1.66	0.21	0.69	0.46	2.55	0.14
CL 82:17; [M-2H](2-)@5.59	ME181844	1.52	0.21	2.09	0.69	0.71	0.35	1.58	0.36
FFA(24:1)	ME181859	0.29	2.50	0.15	1.35	0.26	2.65	0.11	1.27
lysoPE 20:4; [M-H]-@1.35	ME182102	0.24	5.65	0.08	0.06	0.26	3.02	0.09	0.06
IS PS 34:0 ;[M-H]-	ME181866	0.73	1.36	1.39	0.44	0.70	0.97	1.88	0.30
lysoPE 22:4; [M-H]-@1.89	ME182104	0.10	1.35	0.60	1.41	0.15	1.86	0.45	1.72
CL 72:7; [M-2H](2-)@6.08	ME181823	0.96	1.34	0.47	1.43	1.37	0.45	0.51	1.27
lysoPE 16:0; [M-H]-@1.67	ME182095	0.56	3.85	0.10	0.56	0.71	2.84	0.21	0.62
CL 78:5; [M-2H](2-)@7.26	ME181840	1.73	1.29	1.12	0.51	1.50	0.67	1.30	0.39
FFA(18:2)	ME181850	0.08	5.38	0.02	0.15	0.06	4.54	0.03	0.13
lysoPE 20:5; [M-H]-@1.07	ME182103	0.17	5.34	0.06	0.03	0.32	5.11	0.04	0.03
Arachidonic acid	ME181811	0.41	3.43	0.62	0.39	0.36	2.52	0.80	0.34
FFA(24:0)	ME181858	0.09	0.93	0.45	2.00	0.17	0.83	0.52	1.72
IS PE 34:0 ;[M-H]-	ME181863	0.15	3.83	0.76	0.12	0.16	3.19	0.94	0.11
FFA(20:1)	ME181852	0.09	5.72	0.07	0.13	0.05	2.92	0.06	0.12
FFA(22:1)	ME181855	0.84	0.79	0.13	2.15	0.78	0.77	0.16	1.74
PA 36:1; [M-H]-@6.30	ME181869	0.03	0.13	0.12	2.65	0.02	0.19	0.11	2.58
CL 74:9; [M-2H](2-)@9.16	ME181832	0.96	1.17	1.67	0.24	1.00	2.17	1.67	0.22
CL 76:11; [M-2H](2-)@9.09	ME181834	0.96	1.19	1.38	0.32	1.28	2.90	1.64	0.17

Factors:

F1	CONTROL_DIABETIC:db/db diabetic \| Sample type:Kidney
F2	CONTROL_DIABETIC:db/db diabetic \| Sample type:Plasma
F3	CONTROL_DIABETIC:db/db diabetic \| Sample type:Retina
F4	CONTROL_DIABETIC:db/db diabetic \| Sample type:Sciatic Nerve
F5	CONTROL_DIABETIC:db/m control \| Sample type:Kidney
F6	CONTROL_DIABETIC:db/m control \| Sample type:Plasma
F7	CONTROL_DIABETIC:db/m control \| Sample type:Retina
F8	CONTROL_DIABETIC:db/m control \| Sample type:Sciatic Nerve

Data matrix